ArticleEClinicalMedicine2025
Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- Respiratory Syncytial Virus Transmission in Closed Community Settings That Include Children: A Systematic Review and Meta-Analysis.Influenza and other respiratory viruses · 2026Pooled it
- Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Emergence and Global Circulation of the HRSV BA Variant with a 7-AA Extension in the G Protein Under Persistent BA Predominance - Global, 1996-2025.China CDC weekly · 2026Article
- Chandipura virus encephalitis: an emerging pediatric neurotropic threat in india-virology, epidemiology, pathogenesis, and public health challenges.Journal of neurovirology · 2026Review
- Whole-Genome Sequencing of RSV and Phylogeographic Assessment of Viral Importations into Russia.Viruses · 2026Article
- Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Journal of medical virology · 2026Review
- Article
- Article
- Intranasal Delivery of an RSV A2-Derived Pre-F VLP Vaccine Induces Robust Mucosal and Systemic Immunity Against RSV B Strain Without Enhanced Disease.Immune network · 2026Article
- Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Comparative Evaluation of Mucosal Adjuvants for Intranasal Immunization with a Recombinant RSV Prefusion F Protein.Vaccines · 2026Article
- Aging and vaccines: impact of immunosenescence and inflammaging in vaccine response.Frontiers in aging · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal intensive care units. This meta-analysis aims to investigate the prevalence, outbreak size, attack rate, and case fatality rate (CFR) of RSV outbreaks reported globally from 1960 to 2025, as well as to assess variations by geographic region, age group, season, outbreak setting, and viral genotypes. Methods: We compiled a global RSV outbreak dataset by searching publications from database inception to January 31, 2025, across MEDLINE, Embase, Global Health, CINAHL, Web of Science, LILACS, OpenGrey, CNKI, Wanfang, and ChongqingVIP. Studies were eligible if they reported data on laboratory-confirmed HRSV outbreaks in any settings (i.e., hospitals, communities, schools, kindergartens, and long-term care facilities) and among all age groups (pediatric and adult patients). There were no language restrictions (English or Chinese). Studies were excluded if they lacked a clear or inconsistent definition or based solely on serology for RSV diagnosis. We used a standardized form to extract publication characteristics, study location, and outbreak and participant information (prevalence, date and season, age, setting, attack rate, CFR, and genotypes). Two authors independently assessed eligibility, with discrepancies being resolved through discussion with a third author. Random-effects models were used to generate pooled estimates with 95% confidence intervals (CIs). The estimated annual percentage change (EAPC) was calculated to assess temporal trends in prevalence, attack rate, and CFR of RSV outbreaks. The study was registered with PROSPERO under CRD42022303015. Findings: A total of 72 articles from 25 countries were included, reporting 82 RSV outbreaks worldwide involving 2282 cases. Among these, 28 studies (reporting 30 outbreaks) provided information on RSV-related deaths, while 32 studies provided RSV genotype information. The highest outbreak rates were observed in Europe, the Americas, and Asia, especially in the winter season. The most common settings were neonatal intensive care units (30.49%), hematology wards/cancer centers (24.39%), and neonatal wards (15.85%). The median outbreak size was 13 cases (range: 3-588), and RSV-B was the most common genotype (46.88%, 15/32). RSV outbreak reporting increased from 3 in 1960-1970 to 37 in 2010-2025, while the overall CFR decreased from 12.29% (95% CI: 2.51-25.95) in the 1990s to 1.24% (95% CI: 0.01-3.73) in 2010-2025 (p < 0.05). The CFRs were the highest among the elderly (9.24%, 95% CI: 2.75-18.07), in hematology wards/cancer centers (7.56%, 95% CI: 2.56-14.15), and in RSV-A and B co-infections (6.31%, 95% CI: 0.02-18.60). The global pooled attack rate was 35.78% (95% CI: 29.16-42.67), higher in children-related outbreaks (42.29%, 95% CI: 34.53-50.23), neonatal wards (44.67%, 95% CI: 31.76-57.92), and RSV-B genotype studies (46.95%, 95% CI: 35.20-58.87). Interpretation: RSV outbreaks have contributed significantly to global morbidity since the 1960s, with increasing reports over time. While the CFRs have decreased, they remain high in certain subgroups based on age, genotype, and outbreak setting. The pooled attack rate remains substantial, particularly in healthcare settings involving RSV-B genotypes and among immunosuppressed populations. This meta-analysis underscores the importance of targeted vaccination and treatment strategies for controlling RSV outbreaks worldwide in the future. Funding: This study was supported by the Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents and Zhejiang Provincial Disease Control and Prevention Administration (2025JK008) and the Key Program of Health Commission of Zhejiang Province/Science Foundation of National Health Commission (WKJ-ZJ-2523).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.